Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE), a clinical-stage biotechnology company focused on RNA medicines, announced that President and CEO Paul Bolno will participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference in New York City.
The presentation is scheduled for Wednesday, May 20, 2026 at 8:00 a.m. ET, with a live webcast and replay accessible for a limited time via the Investors section of the company website under Investor Events.
Positive
- None.
Negative
- None.
News Market Reaction – WVE
In the May 14 session, WVE declined 1.29%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Q1 2026 earnings | Positive | +8.4% | Reported Q1 2026 results with strong cash and multiple upcoming clinical milestones. |
| Apr 22 | Earnings scheduling | Neutral | -0.5% | Announced timing and access details for the Q1 2026 earnings call and webcast. |
| Apr 21 | Redomiciliation hearing | Neutral | -0.5% | Outlined Singapore High Court hearing schedule for proposed U.S. redomiciliation. |
| Apr 15 | Redomiciliation plan | Neutral | -3.6% | Board approved moving parent company from Singapore to Delaware via share exchange. |
| Mar 26 | Phase 1 INLIGHT data | Positive | -49.6% | Reported positive interim Phase 1 INLIGHT data for WVE-007 with improved body composition. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and earnings updates have sometimes been followed by sharp downside moves, as seen with the INLIGHT Phase 1 data despite favorable wording.
Over the last few months, Wave Life Sciences has reported Q1 2026 results with revenue of $38.2M and a cash position of $544.6M, alongside a noted runway into 3Q 2028. The company announced a proposed redomiciliation from Singapore to the U.S. via a Scheme of Arrangement and detailed this plan in subsequent court and proxy filings. It also released positive interim Phase 1 INLIGHT data for WVE-007. Today’s conference participation notice fits into an active period of financial, strategic, and clinical disclosures since March 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference in New York City on Wednesday, May 20, 2026 at 8:00 a.m. ET.
A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
